Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein, which along with SMARCA4 controls gene regulation through chromatin remodeling, which is in phase 1 clinical trial for the treatment of advanced or metastatic solid tumors; PRT7732, selective and orally bioavailable SMARCA2 degraders, which is in phase 1 multi-dose escalation trial for the treatment of advanced or metastatic solid tumors and; PRT2527, a Cyclin-dependent Kinase 9 inhibitor, which is in phase 1 dose-escalation and confirmation for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Prelude Therapeutics Incorporated

Prelude Therapeutics, Inc. (($PRLD)) has held its Q3 earnings call. Read on for the main highlights of the call. Prelude Therapeutics’ recent earni...

Current Quarter	$-0.33	Next Quarter	$-0.3
Current Year	$-1.51	Next Year	$-1.24
QoQ Growth	+9.1%	YoY Growth	+17.9%
3Y EPS CAGR	+11.6%	Target Price	$3.25
Consensus	Buy	Upside	+94.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRLD	$1.67	+4.37%	429.91K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRLD	$1.67	+4.4%	429.91K
3
4
5
6

PRLD

PRLD

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Prelude Therapeutics Incorporated Data in Excel

Get Prelude Therapeutics Incorporated Data in Excel